Lupuzor (rigerimod): for the treatment of lupus


Lupus is a chronic debilitating incurable inflammatory disease, sometimes fatal, associated with disorders of the immune system.


A look at the science behind Lupuzor™ and its discovery by Europe's largest Research Institution.


A glance at some of the clinical trial results with Lupuzor™ showing improvement in the condition of Lupus patients.


The company behind it

ImmuPharma plc is a drug discovery and development group focusing on novel drugs to treat serious medical conditions with a high unmet need.

With operations in the UK, France and Switzerland, ImmuPharma has a number of compounds in development and a strong proprietary pipeline.

A potential treatment for Lupus

Lupus (or SLE) is a debilitating disease whereby the immune system attacks the body's own tissues.
Lupuzor(TM) has a unique mechanism of action, modulating the immune system to potentially halt disease progression.
Lupuzor™ has started phase III under a Special Protocol Assessment and Fast Track designation by the US FDA.
Lupuzor was discovered by a leading team of scientists at the Centre National de la Recherche Scientifique (CNRS).